News
Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron to present at the 31st European Congress of Psychiatry
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron Announces 2022 Financial Results and Provides Outlook For 2023
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron provides H1 2022 results and updates on R&D and business activities
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology
Recordati Rare Diseases verkündet die Veröffentlichung der Langzeitergebnisse der Verlängerung der Phase-III-Studie LINC 3 zu Isturisa® (Osilodrostat) in Patienten mit Cushing’s Syndrom im European Journal of Endocrinology
Recordati Rare Diseases gab heute die Veröffentlichung der Langzeitergebnisse der offenen Verlängerungsphase der Phase-III-Studie LINC 3 mit Isturisa® im European Journal of Endocrinology bekannt.1
Newron Extends Senior Management Team and Strengthens Commitment to ESG
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
DGAP-News: Newron gibt Ergebnisse der Generalversammlung 2022 bekannt
DGAP-News: Newron announces AGM 2022 results
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease
Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce
Recordati Rare Diseases: Ergebnisse der Phase-III-Studie LINC 4 im Journal of Clinical Endocrinology & Metabolism veröffentlicht; Bestätigung der Wirksamkeit und Sicherheit von Isturisa® (Osilodrostat) bei Patienten mit Morbus Cushing
Recordati Rare Diseases gibt heute die Veröffentlichung der positiven Ergebnisse der Phase-III-Studie LINC 4 zu Isturisa im The Journal of Clinical Endocrinology & Metabolism.1 bekannt. Diese Daten
Newron Announces 2021 Financial Results and Provides Outlook for 2022
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral